Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Pompano Beach, Fla., Dec. 09, 2015 (GLOBE NEWSWIRE) -- DS Healthcare Group’s flagship products are now selling in Walmart, one of Brazil’s largest retailers. With this addition, DS Laboratories further expands its global retail footprint as part of the company’s omni-channel approach and continued dedication to delivering its breakthroughs to consumers worldwide.
Brazilian customers can view our product selection and order at the following link: https://www.walmart.com.br/busca/?ft=ds+laboratories&PS=20
Brazil remains the world's third largest consumer market for toiletries and stands as the world’s second largest market for men’s and children’s hair care products. The partnership with Walmart is expected to drive significant revenue growth for the company in Brazil.
About DS Healthcare Group
DS Healthcare Group Inc. is a leader in the development of biotechnology for topical therapies. It markets through online channels, specialty retailers, distributors, pharmacies, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group's flagship brand, visit www.dslaboratories.com or www.facebook.com/DS.Labs
Forward-looking statements
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov
Investor Relations DS Healthcare Group (888) 404-7770 ext. 3 [email protected]
